Table 1.
Baseline characteristics of the study population.
| Characteristics | All Patients (n = 205) |
Surgical Group (n = 121) |
TACE Group (n = 84) |
|---|---|---|---|
| Sex | |||
| Male | 165 (80.5) | 89 (73.5) | 76 (90.5) |
| Female | 40 (19.5) | 32 (26.4) | 8 (9.5) |
| Age (years) | 60.0 ± 11.7 | 58.1 ± 11.6 | 64.5 ± 11.9 |
| Cause of liver disease | |||
| HBV | 138 (67.3) | 85 (70.2) | 53 (63.1) |
| HCV | 16 (7.8) | 13 (10.7) | 3 (3.6) |
| Non-viral | 51 (24.9) | 23 (19.0) | 28 (33.3) |
| AST (IU/L) | 45 (29.5−94.5) | 45 (30−94.3) | 42 (29−91) |
| ALT (IU/L) | 34 (23−68.5) | 33.5 (23−69) | 33 (22−65) |
| Child−Pugh class | |||
| A | 167 (81.5) | 111 (91.7) | 56 (66.7) |
| B/C | 38 (18.5) | 10 (8.3) | 28 (33.3) |
| Tumor size (cm) | 6.5 ± 4.9 | 4.9 ± 4.5 | 8.8 ± 4.9 |
| Tumor number | |||
| Single | 111 (54.1) | 88 (72.7) | 23 (27.4) |
| Multifocal | 94 (45.9) | 33 (27.3) | 61 (72.6) |
| α-fetoprotein (ng/mL) | 50.3 (5.5−800.8) | 48.4 (5.4−699.1) | 57.4 (5.6−881.4) |
| mUICC stage | |||
| I | 13 (6.3) | 9 (7.4) | 4 (4.8) |
| II | 80 (39.0) | 66 (54.5) | 14 (16.7) |
| III | 49 (23.9) | 29 (24.0) | 20 (23.8) |
| IV | 63 (30.7) | 17 (14.0) | 46 (54.8) |
HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; mUICC, modified Union for International Cancer Control. Data are expressed as mean ± SD or median (interquartile range). Figures in parentheses indicate percentage.